| Literature DB >> 29228967 |
Dominique R Malacarne1, Leslie R Boyd2, Yang Long2, Stephanie V Blank2.
Abstract
BACKGROUND: Risk-reducing bilateral salpingo-oophorectomy (RRBSO) increases survival in patients at high risk of developing ovarian cancer. While many general gynecologists perform this procedure, some argue it should be performed exclusively by specialists. In this retrospective observational study, we identified how often optimal techniques were used and whether surgeons' training impacted implementation.Entities:
Keywords: BRCA; BSO; Best practices; Optimal prophylaxis; Risk reduction
Mesh:
Year: 2017 PMID: 29228967 PMCID: PMC5725804 DOI: 10.1186/s12957-017-1282-5
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Demographics by surgeon group
| Demographic data | General gynecologist ( | Gynecologic oncologist ( |
|
|---|---|---|---|
| Age (mean, SD) | 51.6 (8.78) | 49.1 (8.93) | 0.2 |
| Parity (mean, SD) | 1.45(1.36) | 1.31(1.29) | 0.6 |
| BMI (mean, SD) | 26.1 (5.83) | 25.9 (5.31) | 0.8 |
| Personal Hx of Breast CA ( | 14 (64) | 179 (74) | 0.3 |
| 1st degree relative with breast CA ( | 10 (45) | 106 (44) | 0.9 |
| Known genetic mutation ( | 9 (41) | 104 (43) | 0.9 |
| BRCA mutation status | |||
| BRCA1+ ( | 1 (4) | 47 (20) | 0.09 |
| BRCA2+ ( | 3 (14) | 36 (15) | 1.0 |
| BRCA+, type not specified ( | 2 (9) | 9 (4) | 0.23 |
| BRCA negative ( | 0 | 1 (1) | 1.0 |
| BRCA unknown ( | 16 (73) | 148 (60) | 0.3 |
Fig. 1Percentage of RRBSO techniques performed, by level of training
Fig. 2The percentage of each technique used by gynecologic oncologists when performing RRBSO, by year
Fig. 3The percentage of each technique used by general gynecologist when performing RRBSO, by year
Fig. 4Trend in gynecologic oncologist adherence to all best practice techniques
Characteristics of patients diagnosed with occult malignancy
| Patient | Mutation status | Age | Diagnosis | Prognosis |
|---|---|---|---|---|
| 1 | Unknown | 45 | Metastatic breast cancer to ovary (dx at RRBSO 2007) | Patient last seen 2011: diagnosis right femoral head metastases 2010 s/p XRT |
| 2 | Unknown | 54 | Leydig cell tumor of the ovary | Patient last seen 2012: no evidence of disease |
| 3 | Unknown | 43 | Metastatic breast cancer to ovary (known metastases to lymph nodes) | Lost to follow-up |
| 4 | Unknown | 45 | Metastatic breast cancer to ovary (known metastases to bone) | 2010: new bone metastases; 2012: extensive bone mets, vertebral body compression fractures; 2017: stable lesions, on denosumab |
| 5 | BRCA1+ | 44 | Papillary serous carcinoma of the fallopian tube | s/p 3 cycles carboplatin; no evidence of disease since 2009 |
| 6 | BRCA+ | 44 | Papillary serous carcinoma of the fallopian tube | s/p 6 cycles carboplatin/Taxol; no evidence of disease since 2009 |
| 7 | BRCA2+ | 68 | Papillary serous carcinoma of the fallopian tube | s/p carboplatin/Taxol × 3 cycles; no evidence of disease since 2007 |